

Resource Summary Report

Generated by [NIF](#) on Jul 30, 2026

Brilliant Violet 510™ anti-mouse CD45 Antibody

RRID:AB_2734134

Type: Antibody

Proper Citation

BD Biosciences Cat# 563891, RRID:AB_2734134

Antibody Information

URL: http://antibodyregistry.org/AB_2734134

Proper Citation: BD Biosciences Cat# 563891, RRID:AB_2734134

Target Antigen: CD45

Host Organism: rat

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: Brilliant Violet 510™ anti-mouse CD45 Antibody

Description: This monoclonal targets CD45

Target Organism: mouse

Clone ID: 30-F11

Antibody ID: AB_2734134

Vendor: BD Biosciences

Catalog Number: 563891

Record Creation Time: 20250820T042242+0000

Record Last Update: 20250820T184859+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510™ anti-mouse CD45 Antibody.

No alerts have been found for Brilliant Violet 510™ anti-mouse CD45 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zhang S, et al. (2026) BST2 expression at astrocyte borders promotes microglial recruitment via the C3/C3aR signaling. *Neuron*, 114(1), 67.

Farías MA, et al. (2026) Preclinical characterisation of the protective capacity of an anti-nucleoprotein hRSV monoclonal antibody. *EBioMedicine*, 123, 106104.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.

David M, et al. (2025) Enhanced anti-tumor activity by zinc finger repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs. *Molecular therapy. Oncology*, 33(2), 200989.

Ravi VR, et al. (2025) Lung CD4+ resident memory T cells use airway secretory cells to stimulate and regulate onset of allergic airway neutrophilic disease. *Cell reports*, 44(3), 115294.

Alicea Pauneto CDM, et al. (2025) Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. *Immunity*.

Hu M, et al. (2025) Optimizing anti-PD-1/PD-L1 therapy efficacy and fecal microbiota transplantation donor selection through gut mycobiome-based enterotype. *Cell reports*, 44(5), 115589.

Bian Q, et al. (2025) Maternal natural killer cells drive neuroimmune disorders in offspring through aberrant secretion of extracellular granzyme B. *Immunity*, 58(6), 1502.

Kim DH, et al. (2025) Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis. *Cell reports. Medicine*, 6(4), 102047.

Shimizu K, et al. (2025) Distinct TAM subset with cross-dressing capability determines the bifurcation of tumor immunity. *Cell reports*, 44(6), 115800.

Monticelli S, et al. (2024) Early-wave macrophages control late hematopoiesis. *Developmental cell*, 59(10), 1284.

Hunt EG, et al. (2024) Acetyl-CoA carboxylase obstructs CD8+ T cell lipid utilization in the tumor microenvironment. *Cell metabolism*.

Fang X, et al. (2024) Protocol for building an in vitro model of M2-like tumor-associated macrophages with lactic acid or conditioned medium from Lewis cells. *STAR protocols*, 5(2), 103120.

Cheng M, et al. (2024) ROR γ is required for expansion and memory maintenance of ILC1s via a lymph node-liver axis. *Cell reports*, 43(2), 113786.

Patrick R, et al. (2024) The activity of early-life gene regulatory elements is hijacked in aging through pervasive AP-1-linked chromatin opening. *Cell metabolism*, 36(8), 1858.

Ramachandran M, et al. (2023) Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. *Cancer cell*, 41(6), 1134.

Zucoloto AZ, et al. (2023) Vascular traffic control of neutrophil recruitment to the liver by microbiota-endothelium crosstalk. *Cell reports*, 42(5), 112507.

Johansson K, et al. (2023) An essential role for miR-15/16 in Treg suppression and restriction of proliferation. *Cell reports*, 42(10), 113298.

Huseni MA, et al. (2023) CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. *Cell reports. Medicine*, 4(1), 100878.

Cortellino S, et al. (2022) Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. *Cell reports*, 40(8), 111256.